Do peptides get seized at Irish customs?

Last reviewed 26 August 2026

For an Irish buyer of research peptides, one worry outranks every other: the parcel that never arrives, replaced by a letter. It is not an irrational worry — Irish enforcement detained over three quarters of a million dosage units of illegal medicines in 2025 — but it applies very unevenly, because whether a parcel can be examined at the border depends on whether it ever meets a border at all. This article sets out who detains what, under which rules and in what numbers, what a “research use only” label does and does not change, and which orders the whole machinery never touches.

Every statement here is a statement about a rule, a document or a published figure; none is a statement about what any compound does.

Who examines parcels, and what they detain

Two agencies share the work. Revenue’s Customs Service sits at the postal depots and the sea, air and land frontiers; the Health Products Regulatory Authority (HPRA) holds responsibility for medicines themselves. A memorandum of understanding between them, signed in January 2025, sets the split: Revenue has primary responsibility for the prevention, detection, interception, detention, seizure and investigation of unauthorised and falsified/counterfeit medicinal products at the frontier, and notifies the HPRA’s Enforcement Section of what it finds. Revenue’s own enforcement manual notes that most medicinal products encountered by Revenue are of the nature of small quantities consigned to private individuals for their own personal use — this machinery is aimed at exactly the kind of parcel an online buyer generates.

The numbers are not small. In 2025 the HPRA detained 763,027 dosage units of falsified and illegal medicines, across just under 14,000 individual packages — each linked to a separate purchase by a member of the public. The largest categories were sedatives (205,270 units), erectile-dysfunction products (103,185), anabolic steroids (94,647), diabetes and slimming products (65,148) and analgesics (40,669); 2024’s total was higher still, at 1,000,984 units. Alongside the parcels, 4,762 websites, e-commerce listings and social-media pages were shut down or amended in 2025.

One category moved like no other: GLP-1 products — the semaglutide class — went from 1,582 units detained in 2024 to 48,752 in 2025, much of it in novelty formats such as drops and microneedle patches. The HPRA tested a sample of the detained patches and found they did not contain semaglutide, contrary to the claims on their packaging and promotional materials. That result is worth sitting with: the grey market’s parcels are being detained, and the detained goods are frequently not what they claimed to be either.

The rules doing the work

Three layers of law stand behind a detention. First, unauthorised medicinal products are prohibited or restricted on importation from outside the EU, and Revenue officers are empowered to detain, sample and seize them under the Customs Act 2015. Customs officers are also authorised officers under the Irish Medicines Board Act 1995, entitled to examine and detain products for the purposes of the HPRA’s controls.

Second, the personal-use allowance most people half-remember belongs to travellers, not to the post. A person passing through a customs point may carry a reasonable quantity of their own medicines; Revenue’s manual is explicit that this ‘personal use’ exemption does not apply to products imported by other means, for example by post, by courier or in merchandise.

Third, the supply side is prohibited outright. Regulation 19 of the Medicinal Products (Prescription and Control of Supply) Regulations 2003 states: A person shall not supply by mail order any medicinal product — and the regulations define supply to reach sellers notwithstanding that the person supplied may be in another Member State. Any medicinal product intended for parenteral administration — any injectable — is prescription-only under regulation 5(1)(b), no schedule lookup required. The HPRA’s consumer guidance completes the picture: It is illegal to sell prescription medicines online in Ireland, and a detained product cannot be sent to you or returned to the supplier. It is an illegal product and it may be destroyed. In practice, what the buyer of a detained parcel loses is the product and the money.

Does a “research use only” label protect a parcel?

Less than the sites using it imply. Classification in Irish and EU law runs on two limbs — what a product is presented as, and what it does — and the HPRA’s published classification guide is blunt about the second: any product containing a substance with a known pharmacological effect at that dose level … will usually be classified as a medicinal product by the HPRA irrespective of the presence or absence of claims or medical purpose in the product packaging or literature. A product containing a substance that is prescription-only in Ireland is generally deemed to be a medicinal product requiring an authorisation. So a third-country parcel containing, say, a GLP-1 active is squarely detainable whatever its label says — which is exactly what the 48,752-unit figure records.

For compounds with no authorised medicine counterpart the position is judged case by case, on the totality — claims, labelling, product form, audience, linked websites — and the enforcement record shows where attention actually lands: on products presented as medicines or as consumer treatments, pens, tablets, patches and “weight loss aids”. But the structural point stands. At a customs border, classification is decided by an officer holding your parcel, after your money has already been paid. The legal framework behind all of this is set out in Are research peptides legal in Ireland? The HPRA position.

The parcel that never meets customs

Everything above describes parcels that cross a customs border. Movements inside the EU’s goods arrangements are a different world: Revenue’s own summary of the Ireland/Northern Ireland Protocol is No customs declarations, tariffs or quantitative restrictions. No customs checks or controls on the island of Ireland. A parcel moving to Ireland as intra-EU trade generates no customs declaration, passes no examination point, and produces no An Post charge letter — there is no customs event at which a detention could occur.

That is how NovoVita’s orders travel. We dispatch from UK-held stock, and our orders to Ireland move as intra-EU trade under the Windsor Framework. The position is not a routing trick, and Revenue polices the difference explicitly: Goods that are destined for Ireland, which are shipped through Northern Ireland, continue to be subject to full customs and import requirements — what moves freely is stock genuinely in free circulation, which ours is. The full customs-and-charges analysis, figure by figure, is in Buying research peptides in Ireland: customs and delivery. The United Kingdom side of the same border question — what the MHRA and Border Force stop, and the postal-allowance myth — is covered in the UK mirror of this article.

One honest boundary on the claim: crossing no customs border removes the customs event — it does not change what any product is. Classification law applies inside the State as well as at its edge, which is why our catalogue contains no prescription-medicine actives and our copy makes no medicinal claims. The border question and the legality question are different questions; this article answers the first, and the legality article answers the second.

What this article does not settle

Enforcement figures are updated annually and rules move — check the linked HPRA and Revenue documents rather than a remembered number. Nothing here is a statement about any compound’s effects, and nothing here is advice on how to import anything: it is a description of published rules and published enforcement. Everything NovoVita supplies is for laboratory research use only and is not for human or veterinary use; an entry in the compound library is documentation, not a product. This is analysis, not legal advice.

Sources

• Revenue, Importation and exportation of medicinal products and unauthorised or falsified (counterfeit) medical preparations (Tax and Duty Manual, updated February 2026) — detention powers, the postal reality, the traveller-only personal-use exemption, and the Revenue–HPRA memorandum of understanding.
• HPRA, Over 750,000 units of illegal medicines detained by the HPRA in 2025 (24 March 2026) — the 2025 totals, categories, GLP-1 figures and patch testing.
• HPRA, Over 1 million units of illegal medicines detained by the HPRA in 2024 (30 April 2025) — the 2024 totals and the statement that the supply of online prescription medicines into and within Ireland is illegal.
• HPRA, Dangers of buying prescription medicines online — detention and destruction of illegal products.
• S.I. No. 540 of 2003, Medicinal Products (Prescription and Control of Supply) Regulations 2003 — regulation 19 (mail-order prohibition) and regulation 5(1) (prescription classes, including parenteral products).
• HPRA, Guide to Definition of a Human Medicine (ADV-G0003-8, 21 December 2022) — classification by presentation and by function.
• Revenue, Protocol on Ireland and Northern Ireland and The Windsor Framework — no customs controls on the island; the treatment of goods shipped through Northern Ireland.